' Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma'Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma

For patients with advanced melanoma resistant to anti-PD-L1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent'should be favored'over ipilimumab alone as second-line immunotherapy, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

To understand inter-individual variability of fecal microbe transplantation (FMT) to enhance anti-PD-1 immunotherapy (IT) for melanoma, we analyzed the data sets from two recent publications with a microbial s...
Source: BMC Microbiology - Category: Microbiology Authors: Tags: Research article Source Type: research
We present the most promising metabolic pathways related to desmoplasia and discuss the emerging strategies to improve the efficacy of immunotherapy.PMID:34525931 | DOI:10.2174/1568009621666210825101456
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Source Type: research
ConclusionThis case highlights the potential role of ECT in increasing tumor immunogenicity and consequently in inducing a powerful immune response overcoming primary resistance to checkpoint inhibitor immunotherapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We present a 47 year-old man with a personal history of malignant melanoma (pT3bN2M0) radically removed, who was receiving adjuvant Nivolumab for prevention of recurrence. He was admitted to our service complaining of epigastric pain and hyporexia after receiving the 9º dose of Nivolumab. He underwent a preferential esophagogastroduodenoscopy which showed an intense inflammation limited to the stomach. Macroscopically all the mucosa was erythematosus, edematous, with friability and large ulcerations covered with fibrin. Multiple biopsies revealed inflammatory neutrophilic infiltration in the epithelium, cellular apopt...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Authors: Source Type: research
J Clin Invest. 2021 Sep 14:145296. doi: 10.1172/JCI145296. Online ahead of print.ABSTRACTTumor-infiltrating myeloid cells contribute to the development of the immunosuppressive tumor microenvironment. Myeloid cell expression of arginase 1 (Arg-1) promotes a protumor phenotype by inhibiting T cell function and depleting extracellular L-arginine, but the mechanism underlying this expression, especially in breast cancer, is poorly understood. In breast cancer clinical samples and in our mouse models, we identified tumor derived GM-CSF as the primary regulator of myeloid cell Arg-1 expression and local immune suppression throu...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancer Res. 2021 Sep 13:canres.CAN-21-0164-A.2021. doi: 10.1158/0008-5472.CAN-21-0164. Online ahead of print.ABSTRACTDespite impressive advances in melanoma-directed immunotherapies, resistance is common and many patients still succumb to metastatic disease. In this context, harnessing natural killer (NK) cells, which have thus far been sidelined in the development of melanoma immunotherapy, could provide therapeutic benefits for cancer treatment. To identify molecular determinants of NK cell-mediated melanoma killing (NKmK), we quantified NK cell cytotoxicity against a panel of genetically diverse melanoma cell lines and ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
J Clin Invest. 2021 Sep 14:145296. doi: 10.1172/JCI145296. Online ahead of print.ABSTRACTTumor-infiltrating myeloid cells contribute to the development of the immunosuppressive tumor microenvironment. Myeloid cell expression of arginase 1 (Arg-1) promotes a protumor phenotype by inhibiting T cell function and depleting extracellular L-arginine, but the mechanism underlying this expression, especially in breast cancer, is poorly understood. In breast cancer clinical samples and in our mouse models, we identified tumor derived GM-CSF as the primary regulator of myeloid cell Arg-1 expression and local immune suppression throu...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case publ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
An experimental PET radiotracer can predict whether patients will respond earl...Read more on AuntMinnie.comRelated Reading: PET identifies early responders to liver cancer treatment Second-look PET/CT catches cancer spread FDG-PET/CT aids in melanoma treatment assessment New PET tracer could aid melanoma detection MRI holds promise for immunotherapy but needs more research
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Drug Deliv. 2021 Dec;28(1):1849-1860. doi: 10.1080/10717544.2021.1971797.ABSTRACTMelanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35-40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been attempted. Herein, we assessed whether chlorogenic acid liposomes modified with sialic acid (CA-SAL) combined with anti-PD1 antibody treatment was efficacious as immunotherapy for melanoma. CA-SAL liposomes were prepared and characterized. In a mouse ...
Source: Drug Delivery - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cancer & Oncology | Health | Hematology | Immunotherapy | Melanoma | Skin Cancer | Yervoy